BACKGROUND: Circulating concentrations of 25-hydroxyvitamin D [25-(OH)D] are used to define vitamin D deficiency. Current clinical 25-(OH)D targets based on associations with intermediate markers of bone metabolism may not reflect optimal levels for other chronic diseases and do not account for known seasonal variation in 25-(OH)D concentration. OBJECTIVE: To evaluate the relationship of 25-(OH)D concentration with the incidence of major clinical disease events that are pathophysiologically relevant to vitamin D. DESIGN: Cohort study. SETTING: The Cardiovascular Health Study conducted in 4 U.S. communities. Data from 1992 to 2006 were included in this analysis. PARTICIPANTS: 1621 white older adults. MEASUREMENTS: Serum 25-(OH)D concentration (using a high-performance liquid chromatography-tandem mass spectrometry assay that conforms to National Institute of Standards and Technology reference standards) and associations with time to a composite outcome of incident hip fracture, myocardial infarction, cancer, or death. RESULTS: Over a median 11-year follow-up, the composite outcome occurred in 1018 participants (63%). Defining events included 137 hip fractures, 186 myocardial infarctions, 335 incidences of cancer, and 360 deaths. The association of low 25-(OH)D concentration with risk for the composite outcome varied by season (P = 0.057). A concentration lower than a season-specific Z score of -0.54 best discriminated risk for the composite outcome and was associated with a 24% higher risk in adjusted analyses (95% CI, 9% to 42%). Corresponding season-specific 25-(OH)D concentrations were 43, 50, 61, and 55 nmol/L (17, 20, 24, and 22 ng/mL) in winter, spring, summer, and autumn, respectively. LIMITATION: The observational study was restricted to white participants. CONCLUSION: Threshold concentrations of 25-(OH)D associated with increased risk for relevant clinical disease events center near 50 nmol/L (20 ng/mL). Season-specific targets for 25-(OH)D concentration may be more appropriate than static targets when evaluating health risk. PRIMARY FUNDING SOURCE: National Institutes of Health.
BACKGROUND: Circulating concentrations of 25-hydroxyvitamin D [25-(OH)D] are used to define vitamin D deficiency. Current clinical 25-(OH)D targets based on associations with intermediate markers of bone metabolism may not reflect optimal levels for other chronic diseases and do not account for known seasonal variation in 25-(OH)D concentration. OBJECTIVE: To evaluate the relationship of 25-(OH)D concentration with the incidence of major clinical disease events that are pathophysiologically relevant to vitamin D. DESIGN: Cohort study. SETTING: The Cardiovascular Health Study conducted in 4 U.S. communities. Data from 1992 to 2006 were included in this analysis. PARTICIPANTS: 1621 white older adults. MEASUREMENTS: Serum 25-(OH)D concentration (using a high-performance liquid chromatography-tandem mass spectrometry assay that conforms to National Institute of Standards and Technology reference standards) and associations with time to a composite outcome of incident hip fracture, myocardial infarction, cancer, or death. RESULTS: Over a median 11-year follow-up, the composite outcome occurred in 1018 participants (63%). Defining events included 137 hip fractures, 186 myocardial infarctions, 335 incidences of cancer, and 360 deaths. The association of low 25-(OH)D concentration with risk for the composite outcome varied by season (P = 0.057). A concentration lower than a season-specific Z score of -0.54 best discriminated risk for the composite outcome and was associated with a 24% higher risk in adjusted analyses (95% CI, 9% to 42%). Corresponding season-specific 25-(OH)D concentrations were 43, 50, 61, and 55 nmol/L (17, 20, 24, and 22 ng/mL) in winter, spring, summer, and autumn, respectively. LIMITATION: The observational study was restricted to white participants. CONCLUSION: Threshold concentrations of 25-(OH)D associated with increased risk for relevant clinical disease events center near 50 nmol/L (20 ng/mL). Season-specific targets for 25-(OH)D concentration may be more appropriate than static targets when evaluating health risk. PRIMARY FUNDING SOURCE: National Institutes of Health.
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: B Dawson-Hughes; A Mithal; J-P Bonjour; S Boonen; P Burckhardt; G E-H Fuleihan; R G Josse; P Lips; J Morales-Torres; N Yoshimura Journal: Osteoporos Int Date: 2010-04-27 Impact factor: 4.507
Authors: Cassianne Robinson-Cohen; Ronit Katz; Andrew N Hoofnagle; Jane A Cauley; Curt D Furberg; John A Robbins; Zhao Chen; David S Siscovick; Ian H de Boer; Bryan Kestenbaum Journal: J Clin Endocrinol Metab Date: 2011-04-20 Impact factor: 5.958
Authors: Cassianne Robinson-Cohen; Ronit Katz; Dariush Mozaffarian; Lorien S Dalrymple; Ian de Boer; Mark Sarnak; Mike Shlipak; David Siscovick; Bryan Kestenbaum Journal: Arch Intern Med Date: 2009-12-14
Authors: Ian H de Boer; Bryan Kestenbaum; Abigail B Shoben; Erin D Michos; Mark J Sarnak; David S Siscovick Journal: J Am Soc Nephrol Date: 2009-05-14 Impact factor: 10.121
Authors: Jane A Cauley; Andrea Z Lacroix; LieLing Wu; Mara Horwitz; Michelle E Danielson; Doug C Bauer; Jennifer S Lee; Rebecca D Jackson; John A Robbins; Chunyuan Wu; Frank Z Stanczyk; Meryl S LeBoff; Jean Wactawski-Wende; Gloria Sarto; Judith Ockene; Steven R Cummings Journal: Ann Intern Med Date: 2008-08-19 Impact factor: 25.391
Authors: Anne C Looker; Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Mary Frances Picciano; Elizabeth A Yetley Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: Idris Guessous; William McClellan; David Kleinbaum; Viola Vaccarino; Henry Hugues; Olivier Boulat; Pedro Marques-Vidal; Fred Paccaud; Jean-Marc Theler; Jean-Michel Gaspoz; Michel Burnier; Gérard Waeber; Peter Vollenweider; Murielle Bochud Journal: Clin J Am Soc Nephrol Date: 2015-04-21 Impact factor: 8.237
Authors: James Wang; Kyle A Udd; Aleksandra Vidisheva; Regina A Swift; Tanya M Spektor; Eric Bravin; Emad Ibrahim; Jonathan Treisman; Mohammed Masri; James R Berenson Journal: Support Care Cancer Date: 2016-02-23 Impact factor: 3.603
Authors: Cassianne Robinson-Cohen; Leila R Zelnick; Andrew N Hoofnagle; Pamela L Lutsey; Gregory Burke; Erin D Michos; Steven J C Shea; Russell Tracy; David S Siscovick; Bruce Psaty; Bryan Kestenbaum; Ian H de Boer Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Paulette D Chandler; Julie E Buring; JoAnn E Manson; Edward L Giovannucci; M V Moorthy; Shumin Zhang; I-Min Lee; Jennifer H Lin Journal: Cancer Prev Res (Phila) Date: 2015-03-26
Authors: Soo Lim; Min Joo Kim; Sung Hee Choi; Chan Soo Shin; Kyong Soo Park; Hak Chul Jang; Liana K Billings; James B Meigs Journal: Am J Clin Nutr Date: 2013-01-30 Impact factor: 7.045
Authors: Tapan Mehta; Petra Bůžková; Mark J Sarnak; Michel Chonchol; Jane A Cauley; Erin Wallace; Howard A Fink; John Robbins; Diana Jalal Journal: Metabolism Date: 2014-11-21 Impact factor: 8.694
Authors: Michael C Sachs; Abigail Shoben; Gregory P Levin; Cassy Robinson-Cohen; Andrew N Hoofnagle; Nancy Swords-Jenny; Joachim H Ix; Matthew Budoff; Pamela L Lutsey; David S Siscovick; Bryan Kestenbaum; Ian H de Boer Journal: Am J Clin Nutr Date: 2013-04-24 Impact factor: 7.045
Authors: Gregory P Levin; Cassianne Robinson-Cohen; Ian H de Boer; Denise K Houston; Kurt Lohman; Yongmei Liu; Stephen B Kritchevsky; Jane A Cauley; Toshiko Tanaka; Luigi Ferrucci; Stefania Bandinelli; Kushang V Patel; Emil Hagström; Karl Michaëlsson; Håkan Melhus; Thomas Wang; Myles Wolf; Bruce M Psaty; David Siscovick; Bryan Kestenbaum Journal: JAMA Date: 2012-11-14 Impact factor: 56.272